


 US\$2.54bn  
 Market Cap.

 66.15%  
 Free Float

 US\$5.29mn  
 Avg. Daily Value traded

Research Department

Madhu Appissa, CFA

Tel +966 11 836 5464, appissam@alrajhi-capital.com

## Neutral

### Price Target (SAR): 56.0

Current: 57.8

Upside/Downside: 3.1% below current

### Valuation Multiples 23 24E 25E

	23	24E	25E
P/E (x)	30.5	29.7	28.2
P/B (x)	5.2	5.0	4.7
ROE (%)	17.1	16.5	16.5

### Major Shareholders % Ownership

AI Hammadi Saleh Bin Mohammed	13.16
AI Hammadi Abdul Aziz Bin Mohammed	10.88

### Price Performance 1M 3M YTD

Absolute	-10.8%	-8.0%	-2.7%
Relative to TASI	-8.1%	-11.1%	-7.0%

## Earnings

(SARmn)	2023	2024E	2025E
Revenue	1,177	1,228	1,303
Revenue growth	5%	4%	6%
Gross profit	433	459	495
Gross margin	37%	37%	38%
Operating profit	316	322	347
Op. margins	27%	26%	27%
Net profit	303	312	328
Net margin	26%	25%	25%
EPS	1.90	1.95	2.05
DPS	1.40	1.46	1.23
Payout ratio	74%	75%	60%
P/E	30.5x	29.7x	28.2x
RoE	17.1%	16.5%	16.5%

Source: Company data, Al Rajhi Capital

## Al Hammadi Holding

### Uncertainty around patient volumes for Suweidi

Al Hammadi's Q4 2023 earnings was mixed with topline coming in line supported by better patient yield, but offset by lower volumes, while profitability was weak hurt by higher staff costs as well as higher ECL provisions. The decline in patient volumes was a key concern in Q4, which as per the company was due to the annual reclassification process carried out by insurance companies. This process resulted in the facilities upgraded to class A. During Q4 2023, inpatient volumes declined and stood at 10.5K (-17% y-o-y and +13% q-o-q) whereas Outpatient volumes stood at 275K (-4% y-o-y and +14% q-o-q).


Given that Hammadi is predominantly a B+ operator (55% share), particularly its Suweidi hospital (Q4 inpatient volumes down 20% y-o-y), thus the recent change in reclassification impacted Q4 volumes and has created uncertainty around the patient volumes in the near term. However, some impact can be offset by the company's focus on attracting complex cases by offering discounts and promoting its Suweidi hospital as a class A facility that offers a mix of quality and lower prices. The company can leverage on its Class A patient footfall at Nuzha hospital and divert some of the complex cases to Suweidi by offering them discounted prices. In case the company successfully gains traction in doing so, its revenues could improve despite lower volumes. However, we would prefer to wait for data to indicate the same. To offset lower volumes, the company's move to increase prices by mid-single digit for the insurance category should also help.

Nevertheless, we trim our revenue estimates for 2024 and now expect the topline to grow by slightly over 4% versus earlier estimate of almost 9% y-o-y growth, due to weaker volumes. Further, normalized ECL provisions (2023 benefitted from reversals) should also hurt the operating margin and the bottom line growth in 2024 (+3% y-o-y estimated). We continue to believe that Hammadi is a quality operator with strong balance sheet and its medium to long term growth profile is encouraging, although the growth is skewed towards 2026 and beyond. However, there is lack of clarity of the impact reclassification on its Suweidi hospital. Thus, on the back of lower earnings assumption for 2024 and uncertainty around patient volumes, we reduce our target price to SAR 56/share from SAR 64/share before. At our new target price, the stock implies a downside of 3.1% and neutral recommendation.

Figure 1 Summary of Q1 estimates

(SARmn)	1Q24E	4Q23	3Q23	2Q23	1Q23	1Q24E y-o-y	1Q24E q-o-q
Revenue	298	304	298	277	299	0%	-2%
Gross Profit	108	108	113	92	120	-11%	0%
Gross Margin	36%	35%	38%	33%	40%		
Operating Profit	87	71	87	93	92	-6%	22%
Operating Margin	29%	23%	29%	34%	31%		
Net Income	78	65	75	82	81	-5%	19%
Net Income Margin	26%	21%	25%	30%	27%		

Source: Company Data, Al Rajhi Capital estimates



**Valuations:** Based on the above-mentioned catalysts, we estimate the topline to grow by 4% and 6% in 2024 and 2025, respectively. We assign a P/E multiple of 28x to 2024/2025E EPS and arrive at our new target price of SAR 56/share, offering around 3% downside from the current levels and implying Neutral recommendation on the stock. The key upside risks to our assumptions are recovery in patient volumes at Suweidi supported by referrals from Nuzha and higher growth of MoH patients at Suweidi.

Figure 2  
100)





Figure 3 Valuations

Relative Valuation Multiples	
Forward P/E	28.0x
1BF EPS	2.00
<b>Value per share</b>	<b>56.0</b>
CMP	57.8
Upside/Downside	-3.1%

Source: Bloomberg, Al Rajhi Capital

Source: Company Data, Al Rajhi Capital



## Financials

**Figure 4 Income Statement**

(SARmn)	2023	2024E	2025E
<b>Revenue</b>	<b>1,177</b>	<b>1,228</b>	<b>1,303</b>
Y/Y%	5%	4%	6%
COGS	(744)	(769)	(808)
<b>Gross profit</b>	<b>433</b>	<b>459</b>	<b>495</b>
Y/Y%	3%	6%	8%
<i>Gross margin</i>	37%	37%	38%
Operating Expenses	(98)	(101)	(109)
Impairment of credit losses	(19)	(37)	(39)
<b>Operating profit</b>	<b>316</b>	<b>322</b>	<b>347</b>
<i>Op. margins</i>	27%	26%	27%
Investments and other	31	34	29
Financing Expense	(26)	(26)	(29)
<b>Profit before tax</b>	<b>321</b>	<b>330</b>	<b>347</b>
Zakat & Tax	(18)	(18)	(19)
<b>Net profit</b>	<b>303</b>	<b>312</b>	<b>328</b>
<i>Net margin</i>	26%	25%	25%
EPS	1.90	1.95	2.05
DPS	1.40	1.46	1.23
Payout ratio	74%	75%	60%

Source: Al Rajhi Capital estimates

**Figure 6 Cash Flow Statement**


(SARmn)	2023	2024E	2025E
Cash Flows from Operating Activities	351	441	396
Cash Flows from Investing Activities	(55)	(86)	(195)
Cash Flows from Financing Activities	(232)	(215)	(153)
Change in Cash	65	140	47
<b>Cash &amp; Cash Equivalents at End of year</b>	<b>125</b>	<b>265</b>	<b>312</b>

Source: Al Rajhi Capital estimates

**Figure 5 Balance sheet**

(SARmn)	2023	2024E	2025E
Cash & Cash Equivalents	125	265	312
Receivables, Net	580	553	599
Inventory	57	59	61
Other	22	22	22
<b>Total Current Assets</b>	<b>784</b>	<b>898</b>	<b>995</b>
Fixed Assets	1,533	1,518	1,604
Investment from associates	128	133	137
Right-of-use asset	125	125	125
Intangibles	24	24	24
<b>Total Non-current Assets</b>	<b>1,811</b>	<b>1,799</b>	<b>1,890</b>
<b>Assets</b>	<b>2,594</b>	<b>2,697</b>	<b>2,885</b>
Trade payable	75	77	81
Others	70	70	70
Short-term Debt	38	0	0
Short-term lease liabilities	14	14	14
Other	87	87	87
<b>Total Current Liabilities</b>	<b>284</b>	<b>248</b>	<b>252</b>
Long-Term Debt	164	223	272
Long-term lease liabilities	106	106	106
Other	196	196	196
<b>Total Non-current Liabilities</b>	<b>466</b>	<b>525</b>	<b>574</b>
<b>Total Owners Equity</b>	<b>1,845</b>	<b>1,924</b>	<b>2,058</b>
<b>Total Liabilities</b>	<b>2,594</b>	<b>2,697</b>	<b>2,885</b>

Source: Al Rajhi Capital estimates



## IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

## Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Rajhi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Rajhi.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.


The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.



## Disclaimer and additional disclosures for Equity Research

### Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

### Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

### Contact us

**Mazen AlSudairi, CFA**

Head of Research

Tel : +966 11 836 5468

Email: [alsudairim@alrajhi-capital.com](mailto:alsudairim@alrajhi-capital.com)**Al Rajhi Capital**

Research Department

Head Office, King Fahad Road

P.O. Box 5561, Riyadh 11432

Kingdom of Saudi Arabia

Email: [research@alrajhi-capital.com](mailto:research@alrajhi-capital.com)

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37